Special Issue

Integration of Genomics, Metabolomics, and Host Immunity: A focus of Metabolic Immune System

Message from the Guest Editors

The scope of this Special Issue covers the recent progress in immunological metabolites as they are related to immunology, host immunity, and vaccines. Our key aim is to bring the latest advances in various metabolic approaches for the detection and treatment of various types of diseases. Metabolomics and metabolite profiling research in the field of COVID-19 will be a strong focus in this Special Issue. Further metabolite, immunity, and metabolic pathway development research is more important for the treatment of COVID-19. Additionally, this Issue aims to cover the gene, mRNA, protein, and metabolite-based immunological pathway analysis and the pharmaceutical development and impact on disease prevention.

Guest Editors

Dr. Raja Ganesan

Research Professor, Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, Korea

Dr. Abilash Valsala Gopalakrishnan

Associate Professor, Department Biomedical Sciences, School of BioSciences and Technology, VIT, Vellore, Tamil Nadu, India

Deadline for manuscript submissions

closed (31 July 2023)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/145367

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

